An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
PROVO, Utah, Aug. 4, 2022 /PRNewswire/ — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced second quarter 2022 results. Executive Summary Q2 2022 vs. Prior-year Quarter Revenue: $560.6 million; (20)% (5)% FX impact or $(34.6) […]
Experienced global leader joins dōTERRA executive team PLEASANT GROVE, Utah, July 6, 2023 /PRNewswire/ — dōTERRA, an integrative health and wellness company and world leader in the global aromatherapy and essential oils market, is pleased […]
WEST VALLEY CITY, Utah, May 6, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is thrilled to announce the FDA clearance of two uniquely engineered catheters: the Plato 17—a DMSO-compatible microcatheter—and the Socrates […]
Copyright © 2026 Biotech Networks
